Other Diseases

FDA to review Bristol Myers Squibb’s Sotyktu for psoriatic arthritis

The US Food and Drug Administration (FDA) has accepted for review Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for Sotyktu as a treatment for adults with active psoriatic arthritis.

Rallybio sells REV102 programme to Recursion for up to $25m

Rallybio Corporation has entered into a definitive agreement to sell its interest in the REV102 programme, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP) treatment, to Recursion Pharmaceuticals.

Optime Care collaborates with Tilde Sciences for Vecamyl tablets

AscellaHealth’s Specialty Pharmacy Optime Care has entered into an expanded partnership with Tilde Sciences for Vecamyl (mecamylamine) 2.5mg tablets.

AscellaHealth acquires specialty pharmaceutical wholesaler CHAPPER healthcare

AscellaHealth has acquired CHAPPER healthcare, a specialty pharmaceutical wholesaler, distributor and services provider, for undisclosed amount.

MinervaX collaborates with Wacker Biotech for GBS vaccine production

MinervaX, a Danish biotechnology company, has joined forces with contract development and manufacturing organisation (CDMO) Wacker Biotech for the manufacturing of MinervaX’s active protein ingredients for its Group B Streptococcus (GBS) vaccine.

Celltrion secures new public tenders for two biosimilars in Peru

Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.

UK’s NICE recommends QUVIVIQ to treat chronic insomnia in adults

The National Institute for Health and Care Excellence (NICE) has recommended Idorsia UK’s QUVIVIQ (daridorexant) to treat chronic insomnia in adults.

Eli Lilly and Company completes acquisition of Versanis Bio

Eli Lilly and Company (Lilly) has completed the acquisition of clinical-stage biopharmaceutical firm Versanis Bio.

BioCryst signs agreement with Er-Kim Pharmaceuticals to commercialise ORLADEYO in Turkey

BioCryst Pharmaceuticals has signed a collaboration agreement with Er-Kim Pharmaceuticals for commercialising ORLADEYO (berotralstat) in Turkey.